References
- Wahl B, O’Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 2018;6(7):e744–e757.
- G. B. D. Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1191–1210.
- Georgalis L, Mozalevskis A, Martinez de Aragon MV, et al. Changes in the pneumococcal disease-related hospitalisations in Spain after the replacement of 7-valent by 13-valent conjugate vaccine. Eur J Clin Microbiol Infect Dis. 2017;36(3):575–583.
- European Centre for Disease Prevention and Control. Invasive pneumococcal disease – annual epidemiological report for 2017 2019; [cited 2019 Oct 4]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2017-invasive-pneumococcal-disease.pdf.
- Castiglia P, Pradelli L, Castagna S, et al. Overall effectiveness of pneumococcal conjugate vaccines: an economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy. Hum Vaccin Immunother. 2017;13(10):2307–2315.
- Makwana A, Sheppard C, Borrow R, et al. Characteristics of children with invasive pneumococcal disease after the introduction of the 13-valent pneumococcal conjugate vaccine in England and Wales, 2010-2016. Pediatr Infect Dis J. 2018;37(7):697–703.
- Stockmann C, Ampofo K, Byington CL, et al. Pneumococcal meningitis in children: epidemiology, serotypes, and outcomes from 1997 to 2010 in Utah. Pediatrics. 2013;132(3):421–428.
- European Centre for Disease Prevention and Control. Disease factsheet about pneumococcal disease 2019; [cited 2019 Apr 3]. Available from: https://ecdc.europa.eu/en/pneumococcal-disease/facts.
- Ceyhan M, Ozsurekci Y, Aykac K, et al. Economic burden of pneumococcal infections in children under 5 years of age. Hum Vaccin Immunother. 2018;14(1):106–110.
- Zhang S, Sammon PM, King I, et al. Cost of management of severe pneumonia in young children: systematic analysis. J Glob Health. 2016;6(1):010408.
- Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–451.
- Miller E, Andrews NJ, Waight PA, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011;11(10):760–768.
- Ouldali N, Levy C, Varon E, et al. Incidence of paediatric pneumococcal meningitis and emergence of new serotypes: a time-series analysis of a 16-year French national survey. Lancet Infect Dis. 2018;18(9):983–991.
- van der Linden M, Falkenhorst G, Perniciaro S, et al. Effects of infant pneumococcal conjugate vaccination on serotype distribution in invasive pneumococcal disease among children and adults in Germany. PLoS One. 2015;10(7):e0131494.
- van der Linden M, Falkenhorst G, Perniciaro S, et al. Effectiveness of pneumococcal conjugate vaccines (PCV7 and PCV13) against invasive pneumococcal disease among children under two years of age in Germany. PLoS One. 2016;11(8):e0161257.
- Camilli R, D’Ambrosio F, Del Grosso M, et al. Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure. Vaccine. 2017;35(35):4587–4593.
- Giorgi-Rossi P, Merito M, Borgia P. Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy. Health Policy. 2009;89(2):225–238.
- Fenoll A, Granizo JJ, Gimenez MJ, et al. Secular trends (1990–2013) in serotypes and associated non-susceptibility of S. pneumoniae isolates causing invasive disease in the pre-/post-era of pneumococcal conjugate vaccines in Spanish regions without universal paediatric pneumococcal vaccination. Vaccine. 2015;33(42):5691–5699.
- Harboe ZB, Dalby T, Weinberger DM, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59(8):1066–1073.
- Harboe ZB, Valentiner-Branth P, Benfield TL, et al. Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000-2005. Vaccine. 2008;26(29–30):3765–3771.
- Steens A, Bergsaker MA, Aaberge IS, et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013;31(52):6232–6238.
- Hauser C, Kronenberg A, Allemann A, et al. Serotype/serogroup-specific antibiotic non-susceptibility of invasive and non-invasive Streptococcus pneumoniae, Switzerland, 2004 to 2014. Euro Surveill. 2016;21(21):239.
- Savulescu C, Krizova P, Lepoutre A, et al. Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study. Lancet Respir Med. 2017;5(8):648–656.
- Balsells E, Guillot L, Nair H, et al. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and Meta-analysis. PLoS One. 2017;12(5):e0177113.
- Klugman KP, Rodgers GL. Time for a third-generation pneumococcal conjugate vaccine. Lancet Infect Dis. 2021;21(1):14–16.
- Food and Drug Administration. VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Prescribing Information 2021 [cited 2021 21 July 2021. Available from: https://www.fda.gov/media/150819/download.
- Food and Drug Administration. Prevnar 20 Package insert 2021; [cited 2021 Aug 9]. Available from: https://www.fda.gov/media/149987/download.
- Rupp R, Hurley D, Grayson S, et al. A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Hum Vaccin Immunother. 2019;15(3):549–559.
- Greenberg D, Hoover PA, Vesikari T, et al. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Vaccine. 2018;36(45):6883–6891.
- Ciruela P, Izquierdo C, Broner S, et al. The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage. Vaccine. 2018;36(50):7744–7752.
- Slotved HC, Dalby T, Hoffmann S. The effect of pneumococcal conjugate vaccines on the incidence of invasive pneumococcal disease caused by ten non-vaccine serotypes in Denmark. Vaccine. 2016;34(6):769–774.
- European Centre for Disease Prevention and Control. Surveillance atlas of infectious diseases 2018; [cited 2019 Oct 29]. Available from: https://ecdc.europa.eu/en/surveillance-atlas-infectious-diseases.
- Istituto Superiore Di Sanita. Sorveglianza delle malattie batteriche invasive in Italia 2018; [cited 2019 Oct 29]. Available from: http://old.iss.it/binary/mabi/cont/Report2017.pdf.
- Centre National de Référence des Pneumocoques. Rapport d’activité 2016 2016; [cited 2020 Jul 17]. Available from: https://cnr-pneumo.com/docman/rapports/20-cnrp2016/file.
- Balsells E, Dagan R, Yildirim I, et al. The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: a systematic review and meta-analysis. J Infect. 2018;77(5):368–378.
- Ultsch B, Damm O, Beutels P, et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a european vaccine economics community. Pharmacoeconomics. 2016;34(3):227–244.
- World Health Orgainzation. WHO Guide on Standardization of Economic Evaluations of Immunization Programmes 2019; [cited 2021 May 13]. Available from: https://www.who.int/immunization/documents/who_ivb_19.10/en/.
- Rubin JL, McGarry LJ, Strutton DR, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine. 2010;28(48):7634–7643.
- Office of National Statistics. Birth characteristics in England and Wales: 2018 2019; [cited 2020 July 07]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/livebirths/bulletins/birthsummarytablesenglandandwales/2018.
- Institut National de la Statistique et des Etudes Economiques. 2019 demographic report 2020; [cited 2020 July 07]. Available from: https://www.insee.fr/en/statistiques/2382601.
- DESTATIS Statistisches Bundesamt. Births: population movement 2019; [cited 2019 Oct 22]. Available from: https://www.destatis.de/EN/Themes/Society-Environment/Population/Births/Tables/birth-deaths.html.
- Istituto Nazionale di Statistic. Birth and fertility of the resident population: Year 2018 2019; [cited 2020 July 07]. Available from: https://www.istat.it/en/archivio/237688.
- Statista. Number of births in Spain from 2006. to 2018 2020; [cited 2020 Jul 7]. Available from: https://www.statista.com/statistics/449295/number-of-births-in-spain/.
- Statista. Number of live births in Denmark from 2009 to 2019 2020; [cited 2020 July 07]. Available from: https://www.statista.com/statistics/573245/number-of-live-births-in-denmark/.
- Statistick Sentralbyra Norway. Births 2020; [cited 2020 July 07]. Available from: https://www.ssb.no/en/fodte.
- Federal Statistical Office. Births and deaths 2020; [cited 2020 July 07]. Available from: https://www.bfs.admin.ch/bfs/en/home/statistics/population/births-deaths.html.
- Weinberger R, von Kries R, van der Linden M, et al. Invasive pneumococcal disease in children under 16 years of age: Incomplete rebound in incidence after the maximum effect of PCV13 in 2012/13 in Germany. Vaccine. 2018;36(4):572–577.
- Marchetti M, Colombo GL. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy. Vaccine. 2005;23(37):4565–4576.
- D’Ancona F, Caporali MG, Del Manso M, et al. Invasive pneumococcal disease in children and adults in seven Italian regions after the introduction of the conjugate vaccine. Epidemiol Prev. 2015;39(4 Suppl 1):134–138.
- Munoz-Almagro C, Jordan I, Gene A, et al. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46(2):174–182.
- Santé Publique France. Bulletin EPIBAC n°6 du réseau de surveillance des infections invasives bactériennes 2016; [cited 2019 Oct 22]. Available from: https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infections-a-pneumocoque/documents/bulletin-national/bulletin-epibac-n-6-du-reseau-de-surveillance-des-infections-invasives-bacteriennes.
- Salleras L, Dominguez A, Ciruela P, et al. Changes in serotypes causing invasive pneumococcal disease (2005–2007 vs. 1997–1999) in children under 2 years of age in a population with intermediate coverage of the 7-valent pneumococcal conjugated vaccine. Clin Microbiol Infect. 2009;15(11):997–1001.
- Istituto Superiore Di Sanita. Dati del sistema di sorveglianza delle meningiti batteriche in Italia 1994-2006 2012 [October 29, 2019. Available from: http://old.iss.it/binary/mabi/cont/Report_meningiti_1994_2006.pdf.
- Istituto Superiore Di Sanita. Dati di sorveglianza delle malattie batteriche invasive 2007–2010 2013; [cited 2019 Oct 29]. Available from: http://old.iss.it/binary/mabi/cont/Report_MBI2_2007_2010.pdf.
- Centre National de Référence des Pneumocoques. Rapport d’activité 2003 2003; [cited 2019 Oct 29. 12/07/2018]. Available from: https://cnr-pneumo.com/docman/rapports/7-cnrp2003/file.
- Centre National de Référence des Pneumocoques. Rapport d’activité 2010 2010 [cited 2020 July 17]. Available from: https://cnr-pneumo.com/docman/rapports/14-cnrp2010/file.
- Statens Serum Institut. Overvågning i tal, grafer og kort: pneumokok meningitis, Individuelle anmeldelsespligtige sygdomme; [cited 2020 July 7]. Available from: https://statistik.ssi.dk/sygdomsdata#!/?sygdomskode=PNEU&aldersgruppe=1&xaxis=Aar&yaxis=Total&show=Table&aar=2008%7C2010&datatype=Individual.
- Ingels H, Rasmussen J, Andersen PH, et al. Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme. Vaccine. 2012;30(26):3944–3950.
- Robberstad B, Frostad CR, Akselsen PE, et al. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway. Vaccine. 2011;29(47):8564–8574.
- Venetz I, Schopfer K, Muhlemann K. Paediatric, invasive pneumococcal disease in Switzerland, 1985-1994. Swiss Pneumococcal Study Group. Int J Epidemiol. 1998;27(6):1101–1104.
- Blank PR, Szucs TD. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland. Vaccine. 2012;30(28):4267–4275.
- Kuhlmann A, von der Schulenburg JG. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. Eur J Health Econ. 2017;18(3):273–292.
- Klok RM, Lindkvist RM, Ekelund M, et al. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden. Clin Ther. 2013;35(2):119–134.
- Ess SM, Schaad UB, Gervaix A, et al. Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine. 2003;21(23):3273–3281.
- Agyeman PKA, Schlapbach LJ, Giannoni E, et al. Epidemiology of blood culture-proven bacterial sepsis in children in Switzerland: a population-based cohort study. Lancet Child Adolesc Health. 2017;1(2):124–133.
- Delgleize E, Leeuwenkamp O, Theodorou E, et al. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a markov model. BMJ Open. 2016;6(11):e010776.
- PMSI. Les diagnostics médicaux codés en MCO en 2017 2018; [cited 2019 Oct 29]. Available from: https://www.lespmsi.com/les-diagnostics-medicaux-codes-en-mco-en-2017/.
- PMSI. Tarifs des GHS en 2018 (DGF et OQN) 2018; [cited 2019 Oct 29]. Available from: https://www.lespmsi.com/tarifs-des-ghs-en-2018-dgf-et-oqn/.
- Trading Economics. France labor force participation rate 2019; [cited 2020 Jan 6]. Available from: https://tradingeconomics.com/france/labor-force-participation-rate.
- Journal du Net (JDN). Average salary in France 2020: net, gross, by sex, by CSP 2019; [cited 2020 Jan 6]. Available from: https://www.journaldunet.fr/patrimoine/guide-des-finances-personnelles/1166094-salaire-moyen/#salaire-brut-mensuel-moyen.html.
- Trading Economics. Italy labor force participation rate 2019; [cited 2020 Jan 06 ]. Available from: https://tradingeconomics.com/italy/labor-force-participation-rate.
- Trading Economics. Italy average nominal monthly wages 2019; [cited 2020 Jan 06 ]. Available from: https://tradingeconomics.com/italy/wages.
- Instituto Nacional de Estadistica (INE). Annual average earnings per worker – Year 2017 2019; [cited 2020 Jan 06 ]. Available from: https://www.ine.es/dyngs/INEbase/en/operacion.htm?c=Estadistica_C&cid=1254736177025&menu=ultiDatos&idp=1254735976596.
- Instituto Nacional de Estadistica (INE). Economically active population survey 2019; [cited 2020 Jan 06 ]. Available from: https://www.ine.es/dyngs/INEbase/en/operacion.htm?c=Estadistica_C&cid=1254736176918&menu=ultiDatos&idp=1254735976595.
- Diez-Domingo J, Ridao-Lopez M, Gutierrez-Gimeno MV, et al. Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the valencian public health system (Spain). Vaccine. 2011;29(52):9640–9648.
- Statistics Denmark. Income 2019; [cited 2020 Jan 06 ]. Available from: https://www.dst.dk/en/Statistik/emner/arbejde-indkomst-og-formue/indkomster.
- The World Bank. Labor force participation rate, total 2019; [cited 2020 Jan 06 ]. Available from: https://data.worldbank.org/indicator/SL.TLF.CACT.ZS.
- Statistick Sentralbyra Norway. Earnings 2020; [cited July 2020 07]. Available from: https://www.ssb.no/en/lonnansatt.
- Swiss Federal Office for Statistics. Important labor market indicators, development 2018; [cited 2020 Jan 06 ]. Available from: https://www.bfs.admin.ch/bfs/de/home/statistiken/arbeit-erwerb/erwerbstaetigkeit-arbeitszeit.assetdetail.6526328.html.
- Swiss Federal Office for Statistics. Monthly gross wages by age and gender 2018; [cited 2020 Jan 06 ]. Available from: https://www.bfs.admin.ch/bfs/de/home/statistiken/arbeit-erwerb/loehne-erwerbseinkommen-arbeitskosten/lohnniveau-schweiz/personenbezogene-merkmale.assetdetail.5226961.html.
- Office of National Statistics (ONS). CPI INDEX 06: HEALTH 2015 = 100 2019; [cited 2020 Jan 06]. Available from: https://www.ons.gov.uk/economy/inflationandpriceindices/timeseries/d7bz/mm23.
- Federal Reserve Bank of St Louis (FRED). Harmonized Index of Consumer Prices: Health for Germany 2019; [cited 2019 Jan 06]. Available from: https://fred.stlouisfed.org/series/CP0600DEM086NEST.
- Federal Reserve Bank of St Louis (FRED). Harmonized Index of Consumer Prices: Health for Italy 2019; [cited 2019 Jan 06 ]. Available from: https://fred.stlouisfed.org/series/CP0600ITM086NEST.
- Federal Reserve Bank of St Louis (FRED). Harmonized Index of Consumer Prices: Health for Spain 2019; [cited 2019 Jan 06]. Available from: https://fred.stlouisfed.org/series/CP0600ESM086NEST.
- Statistics Denmark. Consumer price index 2019; [cited 2020 Jan 06 ]. Available from: https://www.dst.dk/en/Statistik/emner/priser-og-forbrug/forbrugerpriser/forbrugerprisindeks.
- Statistick Sentralbyra Norway. Consumer price index 2020; [cited 2020 July 07]. Available from: https://www.ssb.no/en/statbank/table/03014/.
- Federal Reserve Bank of St Louis (FRED). Consumer price index: all items for Switzerland 2020; [cited 2020 July 07]. Available from: https://fred.stlouisfed.org/series/CHECPIALLAINMEI.
- Federal Reserve Bank of St Louis (FRED). Harmonized Index of Consumer Prices: Health for France 2019; [cited 2019 Jan 06 ]. Available from: https://fred.stlouisfed.org/series/CP0600FRM086NEST.
- Nyman JA. Cost recommendations in the second edition of cost-effectiveness in health and medicine: a review. MDM Policy Pract. 2018;3(1):2381468318765162.
- Dasbach EJ, Elbasha EH. Verification of decision-analytic models for health economic evaluations: an overview. Pharmacoeconomics. 2017;35(7):673–683.
- Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010;14(3):e197–e209.
- Tin Tin Htar M, Christopoulou D, Schmitt HJ. Pneumococcal serotype evolution in Western Europe. BMC Infect Dis. 2015;15(1):419.
- Kandasamy R, Voysey M, Collins S, et al. Persistent circulation of vaccine serotypes and serotype replacement after 5 years of infant immunization with 13-valent pneumococcal conjugate vaccine in the United Kingdom. J Infect Dis. 2020;221(8):1361–1370.
- Klugman KP. Herd protection induced by pneumococcal conjugate vaccine. Lancet Glob Health. 2014;2(7):e365–e366.
- Hammitt LL, Akech DO, Morpeth SC, et al. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Health. 2014;2(7):e397–e405.
- Andrews N, Kent A, Amin-Chowdhury Z, et al. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: the indirect cohort design, 2006–2018. Vaccine. 2019;37(32):4491–4498.
- Oligbu G, Collins S, Andrews N, et al. Characteristics and serotype distribution of childhood cases of invasive pneumococcal disease following pneumococcal conjugate vaccination in England and Wales, 2006–2014. Clin Infect Dis. 2017;65(7):1191–1198.
- Silva-Costa C, Brito MJ, Pinho MD, et al. Pediatric complicated pneumonia caused by Streptococcus pneumoniae serotype 3 in 13-valent pneumococcal conjugate vaccinees, Portugal, 2010–2015. Emerg Infect Dis. 2018;24(7):1307–1314.